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Despite the physiological and pharmacological importance of the a1A-adrenoreceptor, the mode of
interactions of classical agonists and radioactive ligands with this receptor is not yet clearly deﬁned.
Here, we used mutagenesis studies and binding experiments to evaluate the importance of 11
receptor sites for the binding of 125I-HEAT, 3H-prazosin and epinephrine. Only one residue (F312)
commonly interacts with the three molecules, and, surprisingly, D106 interacts only with epineph-
rine in a moderate way. Our docking model shows that prazosin and HEAT are almost superimposed
into the orthosteric pocket with their tetralone and quinazoline rings close to the phenyl ring of the
agonist.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction any impact on its afﬁnity. Only a recent publication demonstratedDuring the past few years, crystallography of G protein-coupled
receptors (GPCRs) went through an exponential growth, with the
determination of 25 structures of distinct receptors (http://
gpcr.scripps.edu/index.html). These structures give important
information on the mode of interaction of agonist, antagonist,
inverse agonist and allosteric modulator co-crystallized with dif-
ferent receptors. This is particularly true for the adrenergic recep-
tor family b1- and b2-subtypes for which critical understanding is
now known. At the opposite, a1A-adrenoreceptor (a1A-AR), despite
its therapeutical importance in benign prostatic hyperplasia, has
any atomic structure available. Moreover, delineation of the bind-
ing sites of agonist and the main radioligands used in pharmaco-
logical studies are not yet clearly deﬁned. Indeed, beside partial
exploration, mostly using extrapolation from a1B-AR subtype as
for the involvement of D106 (3.32 in the Ballesteros–Weinstein
numbering for conserved GPCR residues), very few data are avail-
able in the literature. For example, 125I-HEAT is used since decades
as a very potent radioligand and is considered as a competitor of
natural agonists. But all the mutations done on the a1-ARs havethat the F86A variant affects by 25 time HEAT afﬁnity [10]. F86 is
located at the top of the transmembrane domain II and is far from
around 12 and 23 Å to D106 and S192, respectively, two positions
published to be important for epinephrine and prazosin binding
[1,8]. The purpose of this work is to deﬁne a1A-AR residues impli-
cated in HEAT, prazosin and epinephrine binding, and to propose a
docking model of these three interactions.
2. Materials and methods
125I-HEAT and 3H-prazosin were purchased from PerkinElmer
(Courtaboeuf, France). Non-radioactive HEAT was obtained from
Tocris (Ellisville, Missouri, USA), and prazosin and epinephrine
from Sigma–Aldrich (St. Quentin-Fallavier, France).
2.1. Site-directed mutagenesis
a1A-AR cDNA inserted in the prK5 vector was kindly provided
by Michael Brownstein (Craig Venter Institute, Rockville, MD).
Point mutations were introduced into the a1A-AR gene by sense
and antisense primers (Sigma–Aldrich, St. Quentin-Fallavier,
France) containing the desired changes, using the QuikChange
Site-Directed Mutagenesis kit. The incorporation of each mutation
was veriﬁed by DNA sequencing. The variants F308A and F312A
4614 A. Maïga et al. / FEBS Letters 588 (2014) 4613–4619were generous gifts from Dr. Diane Perez (The Cleveland Clinic
Foundation, Cleveland, Ohio, USA).
2.2. Cells culture and membrane preparation
CHO cells stably expressing a1-ARs were kindly provided by
Dr. Hervé Paris (INSERM U858, Toulouse, France) and were grown
in a 50:50 Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)/Ham’s
F12 medium supplemented with 10% fetal bovine serum, gluta-
mine (2 mM), penicillin (100 units/ml) and streptomycin (100 lg/
ml) at 37 C with 5% CO2. COS-7 cells were grown in Dulbecco’s
modiﬁed Eagle’s medium containing 10% fetal calf serum, 1% pen-
icillin and 1% glutamine. At 80% conﬂuence, cells were transfected
using a calcium phosphate precipitation method for transient
expression of the genetic construct. At conﬂuence, cells were har-
vested and membranes were prepared as described [10]. Mem-
brane protein concentrations were determined using the Bio-Rad
protein assay, with bovine serum albumin as standard.
2.3. Binding assays
Binding experiments were performed in a 100 ll reaction mix
at room temperature in buffer (50 mM Tris–HCl, pH 7.4, 10 mM
MgCl2, 1 g/l BSA). Incubation was stopped by ﬁltration through0
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Fig. 1. Inhibition of the binding of a series of concentrations of 125I-HEAT to a1A-AR by p
proteins) inhibited by prazosin (full lines) and epinephrine (dashed lines). Errors bar we
Prusoff equation IC50 = Ki + Ki(L/Kd), of IC50 values as a function of the radiotracer concen96 GF/C ﬁlter plates pre-incubated with 0.5% polyethylenimine.
25 ll of Microscint 0 were added onto each dry ﬁlter and the
radioactivity was quantiﬁed on a TopCount beta counter with a
33% yield (PerkinElmer, Courtaboeuf, France). Saturation binding
assays were performed using a ﬁx amount of receptors (1 lg or
0.1 lg of a1A-AR CHO cell membranes for 3H-prazosin or 125I-HEAT,
respectively, or a1A-mutant COS-7 cell membranes between 0.1
and 20 lg) and increased concentrations of 3H-prazosin or
125I-HEAT with an incubation time of 2 or 16 h. Non-speciﬁc
binding were measured in the presence of 1 or 10 lM of Prazosin.
Competition binding assays were performed as follows: a1A-AR
membranes (0.1 lg) or a1A-mutants (1–20 lg) were incubated
for 2 or 16 h with 125I-HEAT (200 pM) and a range of competitor
concentrations. Dissociation kinetics experiments were performed
by pre-equilibrating 3 h 125I-HEAT or 3H-prazosin with a1A-AR COS
cell membranes. Radiotracer associations were then stopped by the
addition of prazosin (10 lM).
2.4. Data analysis
Data were analyzed by non-linear regression using the
KaleidaGraph 4.0 software (Synergy software, Reading, PA). KD
and Bmax values are determined by applying the non-linear
regression BS = (Bmax * A)/KD + A. Data from competition binding10-5 0,001
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estimation. Ki are determined from the IC50 values of using the
Cheng and Prussof equation [4]. The linear curves were analyzed
with IC50 = Ki + (L/KD) * Ki. Dissociation kinetics were analyzed
using a simple equation of exponential decay BS * exp(Koff⁄ t).
Results are expressed as mean ± S.E. mean from n independent
experiments. One-way Anova test was used to compare values. A
P < 0.05 was accepted for statistical signiﬁcance.
2.5. Homology modeling
A model of the a1A-AR was generated with MODELLER [16]
using the b2-AR subtype which shared 21% sequence identity with
a1A-AR, has a Ca RMSDs less than 1.5 Å for 253 residues [7] and
using the highest resolution structure (2RH1) as a template [19].
2.6. Docking
Ligands docking were performed manually with Pymol (PyMOL
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Fig. 2. Saturation experiments with 125I-HEAT (open symbols) and 3H-prazosin (full
symbols) on receptor variants, graphically separated depending of their expression
levels, Panel A and B for high and low expression level, respectively. Color code:
black, wild-type (0.2 and 2 lg of protein for 125I-HEAT and 3H-prazosin, respec-
tively), Green, E87A (0.2 and 2 lg of protein for 125I-HEAT and 3H-prazosin,
respectively), Blue F288A (0.05 and 2 lg of protein for 125I-HEAT and 3H-prazosin,
respectively), red F312A (0.05 and 12 lg of protein for 125I-HEAT and 3H-prazosin,
respectively), brown D106A (2.2 and 25 lg of protein for 125I-HEAT and 3H-
prazosin, respectively), light blue W313A (1.2 and 12 lg of protein for 125I-HEAT
and 3H-prazosin, respectively). n from 2 to 8.2004. DeLano Scientiﬁc LLC. All Rights Reserved). The starting posi-
tions of manual dockingwere driven by literature and experimental
results (see Section 3). Next, the structures of the complexes
obtained were minimized (500 steps). To judge of the complexes
stability, short molecular dynamics were performed (10000 steps).
Hydrogen atomwere built with the CHARMM22 [9] and Hbuild. All
unstable complexes were rejected and a new manual docking was
performed. During all the calculation, backbone and Cb atoms were
kept ﬁxed allowing the side chain ﬂexibility, and the structure of
the ligandwasmaintained by harmonic restraints of 100 kcal mol1
allowing complete rotation and translation of the ligand. The calcu-
lations were performed with CHARMM package version c33b2 ver-
sion and force ﬁelds CHARMM22 [9] on a local cluster of 22 amd
Opteron processors. Theminimization algorithm usedwas Adopted
Basis Newton–Raphson. The dynamics integrator was Verlet. All
bond length of hydrogen atoms were constrained using SHAKE
algorithm and a time step of 2 fs has been used [15].3. Results and discussions
3.1. Full competition between prazosin, HEAT and epinephrine
We ﬁrst intend to demonstrate a competition mode of action
between the two antagonists prazosin and HEAT and the agonist
epinephrine on a1A-AR. Competitions of six 125I-HEAT concentra-
tions (1.56, 1.01, 0.74, 0.52, 0.28 and 0.12 nM for prazosin and
1.50, 1.21, 0.91, 0.60, 0.30 and 0.11 nM for epinephrine) by prazo-
sin and epinephrine were performed given IC50 of 47.1, 36.2, 25.8,
14.5, 9.70 and 4.61 nM for prazosin and 35.1, 22.9, 20.4, 14.9, 6.63
and 3.91 lM for epinephrine. Hill slopes were all between 0.83 and
1.11 (Fig. 1A). The two sets of points ﬁtted the linear regressions
IC50prazo = 1.197 + 30.90 * L and IC50epi = 1.154 + 21.07 * L (Fig. 1B).
According to the Cheng and Prusoff equation (IC50 = Ki + (L/KD) * Ki),
the extracted Ki are 1.197 nM (pKi 8.92) and 1.154 lM (pKi 5.94) for
prazosin and epinephrine respectively [4]. HEAT KD are 0.0387 nM
(pKD 10.41) and 0.0548 nM (pKD 10.21), extracted from prazosin
and epinephrine competitions, respectively. IC50 evolved linearly
with the radiotracer concentration and the afﬁnity constants are
in accordance with those determined by direct saturation and
competition experiments (Fig. 2 and Table 1), demonstrating that
HEAT is a true competitor of prazosin and epinephrine.3.2. The speciﬁc case of the aspartic acid residue D106
The negative charge of the aspartic acid in position 3.32 (D106
on a1A-AR) is the most conserved residue across all of the biogenic
amine receptors [17] and is claimed to form a salt bridge with the
positive charge of the biogenic amine. Contradictory results exist in
the literature concerning the inﬂuence of this aspartic acid on the
binding of antagonists or agonists of a1-ARs. On a1B-AR, the
mutation D125A was described to have no inﬂuence on either
HEAT or prazosin afﬁnities in one publication [12], two other
papers proposed a strong inﬂuence on both ligands binding
[2,18]. On a1D-AR, the group of Nagatomo [11] found that D176A
displayed any afﬁnity for prasozin. The single work done on
a1A-AR concludes that this mutation destroyed 3H-prazosin afﬁnity
[1]. However, the study does not report the expression level of the
mutant at membrane surface, excluding a clear explanation of this
result. Our result indicate that D106A a1A-AR receptor was very
difﬁcult to express with a Bmax around 0.6 pmol/mg, 30-times
lower as compared to the wild-type receptor (Table 1, [10]). By
homologous and heterologous binding experiments we unambigu-
ously demonstrated that the D106A variant affect only epinephrine
afﬁnity, and in a moderate manner (5.3 times afﬁnity decrease),
with no change in prazosin or HEAT afﬁnities.
Table 1
Radioligand binding on wild-type and mutated a1A-AR receptors.
Variants Positions 3H-prazosin 125I-HEAT
Bmax
pmol/mg
pKD n Kd
ratio
Bmax
pmol/mg
pKD n Kd
ratio
WT 17 ± 3 9.26 ± 0.05 6 1.0 11.3 ± 2.3a 10.05 ± 0.14a 8 1
F86A 2.64 32.6 ± 5.6 9.21 ± 0.1 3 1.1 22.6 ± 2.4a 8.68 ± 0.09***,a 4 23
E87A 2.65 18.8 ± 2.3 9.38 ± 0.21 2 0.75 15.6 ± 1.1 9.3 ± 0.05** 4 5.6
D106A 3.32 0.56 ± 0.12 9.66 ± 0.55 4 0.40 0.63 ± 0.05a 9.82 ± 0.11 a 4 1.7
F187A 5.41 14 ± 2.2 9.60 ± 0.03 2 0.46 20.5 ± 3.5a 10.70 ± 0.01a 3 0.22
S188A 5.42 16 ± 1 9.40 ± 0.08 2 0.72
SS-AA 3.0 ± 1 8.35 ± 0.05** 3 8.1 13.3 ± 3.3a 10.15 ± 0.01a 2 0.78
S192A 5.46 35 ± 3 9.52 ± 0.04 3 0.55
F288A 6.51 12 ± 1.5 9.33 ± 0.08 4 0.85 44.9 11.1 ± 0.06*** 3 0.09
M292A 6.55 15.8 ± 3.5a 9.69 ± 0.09a 2 2.2
F308A 7.35 9 ± 3 8.89 ± 0.12 2 2.3 29 ± 4.2a 9.66 ± 0.11a 2 2.4
F312A 7.39 2.1 ± 1 8.15 ± 0.42*** 4 13 67 ± 6.1a 10.97 ± 0.07*** 3 0.12
W313A 7.40 1.21 ± 0.6 9.34 ± 0.04 2 0.83 2.65 ± 0.8 9.46 ± 0.11 4 3.9
** P < 0.05.
*** P < 0.01.
a Maiga et al. [10].
Table 2
Ligand-binding proﬁles of wild-type and mutant a1A-AR using 125I-HEAT.
Variants Positions Prazosin
pKi
Ki
ratio
HEAT
pKi
Ki
ratio
Epinephrine
pKi
Ki
ratio
WT 9.18 ± 0.07 1 9.57 ± 0.08a 1 6.0 ± 0.07 1
F86A 2.64 8.8 ± 0.04 2.3 8.21 ± 0.09***,a 23 6.4 ± 0.09 0.4
E87A 2.65 9.03 ± 0.09 1.3 8.89 ± 0.08** 4.8 6.35 ± 0.08 0.4
D106A 3.32 9.4 ± 0.11 0.6 9.74 ± 0.12a 0.7 5.3 ± 0.08** 5.1
F187A 5.41 9.7 ± 0.06 0.3 9.76 ± 0.07 0.65 5.4 ± 0.1** 4.6
SS-AA 8.4 ± 0.06** 5.5 5.1 ± 0.06** 8.1
F288A 6.51 9.3 ± 0.12 0.8 10.25 ± 0.1** 0.21 3.6 ± 0.05*** 250
M292A 6.55 8.8 ± 0.09 2.7 5.3 ± 0.14** 4.8
F308A 7.35 8.9 ± 0.09 1.7 5.5 ± 0.05 3.4
F312A 7.39 8.1 ± 0.11*** 12 10.2 ± 0.05** 0.23 5.2 ± 0.07*** 6.3
W313A 7.40 9.2 ± 0.05 1 8.92 ± 0.1** 4.5 5.8 ± 0.12 1.8
** P < 0.05.
*** P < 0.01.
a Maiga et al. [10].
Table 3
Half live time of 3H-prazosin and 125I-HEAT on a1A-AR variants.
3H-prazosin 125I-HEAT
T1/2, min Ratio n T1/2, min Ratio n
WT 38 1 5 65 1 5
F86A 22 0.58 3 2.45 0.038 3
E87A 39 1.05 2 62 0.95 2
F288A 11 0.29 3 271 4.2 3
F312A 3 0.079 3 377 5.8 3
W313A 26 0.68 2 6.5 0.1 3
4616 A. Maïga et al. / FEBS Letters 588 (2014) 4613–46193.3. An unusual role of the two phenylalanine residues 288 and 312
pKD of prazosin measured from direct saturation binding at
equilibrium (Table 1) and pKi from inhibition of 125I-HEAT binding
(Table 2) are similar for each of receptor constructions, except for
the F288A and F312A variants. Indeed, on F288A mutant, prazosin
pKD (9.33) is signiﬁcantly higher than its pKi (8.03, results not
shown). The same discrepancy was observed on F312A with a
pKD of 8.15 while its pKi is 7.25 (results not shown). Despite the
fact that these two pKi are in accordance with the literature
[3,21], pKi and pKD should be similar as HEAT and prazosin are
competitors. We veriﬁed if the experiments were performed under
equilibrium conditions by measuring dissociation kinetic rates. On
F288A and F312A, 125I-HEAT Koff are 2.56 ± 0.22 and 1.84 ±
0.12 * 103 min1 M1, respectively, being signiﬁcantly slower
compared to the wild-type receptor (10.7 ± 0.87 * 103 min1 M1,
Table 3 and Fig. 3). On the same receptor variants, 3H-prazosin Koff
were faster with kinetic dissociation constants increased by 3.4
(KoffF288A 63.0 ± 4.2 * 103 min1 M1) and 12.6 times (KoffF312A
231 ± 28 * 103 min1 M1) respectively, compared to wild type
receptor (18.2 ± 3.2 * 103 min1 M1). It is clear that 2 h of
incubation time is not long enough to reach equilibrium for
complexes having half live of 271 and 377 min. We thus performed
new 125I-HEAT binding experiments with 16 h incubation time on
these two receptor variants. 125I-HEAT pKD on WT receptor was
identical than with 2 h incubation times (Bmax 15.6 ± 2.1 pmol/mg, pKD 10.2 ± 0.07) while on F288A and F312A, its pKD increased
by 11 and 8.3 times (Table 1). Under this long incubation time, pra-
zosin pKi did not change on wild-type receptor (pKi = 9.2 ± 0.1,
result not shown) but were of 9.3 and 8.1 on F288A and F312A,
respectively. These pKi values are now in perfect accordance with
the prasozin pKD obtained by direct saturation experiment. Using
appropriated incubation time, F288 and F312 are now two posi-
tions identiﬁed as important for HEAT binding. For prazosin, it
appeared that F288 is not implicated in its binding, while F312
is. It is worth mentioning that previous results describing that
the mutation F310A on a1B-AR (position 6.51, F288 in a1A-AR)
affects by 44 times prazosin afﬁnity has been done with 125I-HEAT
as a tracer and a short 1 h incubation time [3]. If this mutation on
a1B-AR affects HEAT pharmacological parameters by the same way
than on a1A-AR, we would suggest to re-evaluate the result with
F288A
F312A
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W313A
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B
Fig. 3. Dissociation experiments of 125I-HEAT (Panel A) and 3H-prazosin (Panel B).
After 3 h incubation time with wild-type or mutated receptors (same color code and
amount of membranes than in Fig. 2), 10 lM of prazosin was added and
dissociations were followed. Errors bar were omit for clarity and were of the size
of the symbols. n from 2 to 5.
prazosin
HEAT
Epinephrine
**
***
**
**** **
**
**
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**
Fig. 4. Afﬁnity ratios for prazosin (blue), HEAT (green) and epinephrine (red)
expressed as the log of Ki WT versus Ki variants. ⁄⁄P < 0.05, ⁄⁄⁄P < 0.01.
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mutation on various ligands afﬁnities, using 1 h incubation time
[21]. These results should also be conﬁrmed with longer incubation
time. Finally, we investigated the inﬂuence of these two mutations
on epinephrine afﬁnity and conﬁrm that both positions are impor-
tant for its binding (Table 2).
3.4. Epinephrine and prazosin binding sites
From the analysis of mutations F187A, S188A, S192A, M292A,
F308A and the double SSAA, 125I-HEAT afﬁnities were not signiﬁ-
cantly affected (Table 1, [8,10]). Prazosin afﬁnity was reduced by
8 times by the double mutation S188/S192 (Tables 1, 2 and Figs. 2,
3). On its own, epinephrine afﬁnity was slightly decreased by 5
times by M292A construction and in concordance with previous
mutagenesis studies, the double mutation SS/AA and the F187A
also affect the agonist binding (8.1 and 5 times respectively). Inter-
estingly neither S188A nor S192A alone decrease the afﬁnity of the
prazosin and the epinephrine, that have been demonstrate by Hwa
and Perez as due to the competition of the catechol hydroxyls for
the remaining serine residue [8].
3.5. Speciﬁc interaction points for HEAT
We explored positions around the F86 (important position for
HEAT afﬁnity [10] and identiﬁed E87 and W313 as possiblepositions in interaction with HEAT. Both mutations E87A and
W313A slightly affect by 4.8 and 4.5 times 125I-HEAT afﬁnity, with-
out modifying neither prazosin nor epinephrine afﬁnities. Interest-
ingly, 125I-HEAT dissociation rate is not affected by the E87A
construction (Table 3 and Fig. 3). Consequently, this mutation
should slow down 125I-HEAT association rate, suggesting that the
positive charge on the secondary amine of HEAT may form an ionic
bridge with the negative one of the glutamic acid residue 87 with a
role in bringing the two molecules.
3.6. Docking model
HEAT interacts with F86, F288, F312, W313 and E87, prazosin
with F312, S188 and S192 and epinephrine with D106, F187,
S188, S192, F288, M292 and F312 (Fig. 4). Docking of epinephrine,
prazosin and HEAT were performed taking into account these
interactions in term of proximity between ligands and a1A-AR
receptor. Epinephrine nitrogen and its hydroxyls group were posi-
tioned close to the negative charge of the aspartic 3.32 and to the
serine residues, respectively, two contacts already identiﬁed [14].
Prazosin methoxy groups were docked close to the TM 5 domain
in order to establish link with the serine S188 (5.42) and S192
(5.46). Finally, as the iodinated HEAT displays the same afﬁnity
than the non-iodinated form, we presume that HEAT hydroxy-
phenyl ring can be hardly located deeply inside the binding pocket
of the receptor and thus oriented HEAT molecule with its hydroxy-
phenyl ring pointed outside the orthosteric pocket. Using Pymol
(http://www.pymol.org), ligands were manual docked in the
homology model of a1A-AR receptor and their location optimized
by molecular dynamics (see Section 2). The resulting structures
are presented on Fig. 5. Comparison of the epinephrine binding
sites proposed in our model to that one observed in an active state
of the b2-AR stabilized with a nanobody highlight high similarities
in the agonist location [14]. For example, both models show an
angled agonist establishing hydrogen bounds between the con-
served D106 (3.32) and its nitrogen and between serines S188
(5.42) and S192 (5.46) and hydroxyls in meta and para of the cate-
cholamine respectively. However if the phenyl ring in b2-AR seems
to interact with F193 in the ECL2, V117(3.36) and F290 in TMVI, in
a1A-AR model it appears to be more close to the hydrophobic res-
idues of the TMVI, F288 and M292. The equivalent b2-AR N193 that
interact with the b-hydroxyl of epinephrine is still unknown for
a1A-AR. However, the positions F312(7.39) and F187(5.41) high-
lighted in this study as important for epinephrine binding, appear
in our model far from the ligand, suggesting that the real structure
Fig. 5. Homology modeling of ligands binding site in the a1A-AR. Indicated in red
residues involved in the binding of epinephrine (A), HEAT (B) and Prazosine (C).
Transmembrane domains of the receptor are represented in grey, the structure of
epinephrine in magenta, HEAT in blue and prazosin in yellow.
4618 A. Maïga et al. / FEBS Letters 588 (2014) 4613–4619of the receptor could have some differences with the proposed
model allowing more proximity between identiﬁed residues and
the agonist b-hydroxyl.
HEAT and prazosin adopt a very similar organization into the
orthosteric pocket even if they interact with different receptor
positions, except the common F312. The methoxy groups ofprazosin are close to the S188 and S192, consistent with the struc-
ture of b2-AR in complex with different inverse agonists (carazolol,
timolol, ICI118551) showing a hydrogen bound between the
Ser203 and the polar group in the aromatic ring of ligands
[5,6,13,20]. On the other hand, the hydrophobic residue F312 is
close to the furan tail of prazosin. HEAT displays the same afﬁnity
with or without its iodine moiety and the proposed docking directs
its hydroxyphenyl ring close to the external part of the receptor.
This ring is close to the hydrophobic residues F86, F312 and
W313 while its tetralone and quinazoline rings interacts with
F288. In comparison the antagonist aprenolol aromatic ring inter-
acting with V114 (3.33) and F290 (6.52) in the structure of b2-AR
in complex with the ligand [20]. Curiously, HEAT displays the same
afﬁnity for the three a-ARs while the position 86 is occupied by a
leucine in the a1B-AR and a methionine in the a1D-AR. A deeper
exploration of that position should be done to better understand
the role of this position in HEAT afﬁnity. Unlike the structures of
b2-AR in complex with antagonist or inverse agonists, where the
conserved D113 (3.32) establish hydrogen bound with the com-
pound amine, our models do not show any involvement of the res-
idue into the binding of the prazosin and HEAT. That might be
explained by the distance between D106 and the amine moiety
of HEAT susceptible to establish hydrogen bound.
In conclusion our study report for the ﬁrst time an extensive
evaluation of the binding sites of 3 commonly used ligands of
a1A-AR. Recent resolution of GPCR structures proved especially
for adrenergic GPCR that the mutagenesis result are reliable, if
the overall structure of the receptor is not affected. In this study
we have characterized most of our mutants by direct binding
assays using two radio labeled ligands. Except for F312 variant,
all the others mutations never affect afﬁnities of all the three tested
ligands, strongly suggesting that the general shape of the receptor
was preserved. To deﬁnitively distinguish between a direct and
indirect impact it might be necessary to use modiﬁed ligands,
not yet available, and carry out a double cycle mutation. The pres-
ent study corresponds to the ﬁrst step and the proposed complexes
are not the only one possible but are plausible complexes, compat-
ible with experimental data. The models show some similarities
with binding sites of b2-AR structures but many differences high-
lighting variations between these receptors activation and func-
tionality. One illustrating example is the aspartic residue D3.32
which is not implicated antagonists afﬁnities in a1A-AR and not
crucial either for epinephrine. Taking into consideration the thera-
peutic importance of a1A-AR in benign prostatic hyperplasia, our
proposed models are susceptible to lead to the conception of more
efﬁcient and selective drug against the disease.
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